Abstract Number: 2821 • 2014 ACR/ARHP Annual Meeting
Efficacy and Safety/Tolerability of Mavrilimumab, a Human GM-CSFRá Monoclonal Antibody in Patients with Rheumatoid Arthritis
Background/Purpose Granulocyte-macrophage colony-stimulating factor (GM-CSF) is implicated in RA pathogenesis via myeloid and granulocyte cell lineage activation. In a prior Phase 2a study (NCT01050998), mavrilimumab,…Abstract Number: 1557 • 2014 ACR/ARHP Annual Meeting
Clinical Response in Subjects with Psoriatic Arthritis Following One Year of Treatment with Brodalumab, an Anti-Interleukin-17 Receptor Antibody
Background/Purpose: Interleukin-17 (IL-17) plays a role in the pathogenesis of psoriatic disease of both skin and joint. We sought to assess long-term efficacy and safety…Abstract Number: 282 • 2014 ACR/ARHP Annual Meeting
Pharmacovigilance in Juvenile Idiopathic Arthritis Patients (PHARMACHILD) Treated with Biologic Agents and/or Methotrexate. Consolidated Baseline Characteristics from Pharmachild and Other National Registries
Background/Purpose The availability of methotrexate (MTX) and biological agents has provided a major change in the treatment of children with juvenile idiopathic arthritis (JIA). However,…Abstract Number: 2824 • 2014 ACR/ARHP Annual Meeting
A Profile of the Efficacy of Sarilumab Plus Methotrexate in Rheumatoid Arthritis Patients: Results of a 52-Week, Phase 3, Randomized, Double-Blind, Placebo-Controlled, International Study
Background/Purpose Interleukin-6 (IL-6) regulates a diverse array of activities that may underlie systemic and local symptoms of rheumatoid arthritis (RA). The efficacy of sarilumab, a…Abstract Number: 1524 • 2014 ACR/ARHP Annual Meeting
Rituximab Done! What’s Next in RA?
Background/Purpose The optimal strategy to use biologics after rituximab (RTX) in RA is unknown. We therefore aimed to evaluate the effectiveness of different biologics after…Abstract Number: 274 • 2014 ACR/ARHP Annual Meeting
Treatment Prescribing Patterns in a Cohort of Patients with Juvenile Idiopathic Arthritis (JIA). Data from the Childhood Arthritis Prospective Study
Background/Purpose: Juvenile idiopathic arthritis (JIA) is a heterogenous disease, classified according to the International League of Associations for Rheumatology (ILAR). Initial treatment is based largely…Abstract Number: 2795 • 2014 ACR/ARHP Annual Meeting
Blockade of IL-6R Signaling by Sarilumab Suppressed Circulating Markers of Bone Resorption and Synovial Damage in Rheumatoid Arthritis Patients from a Phase 3, Randomized, Double-Blind, Placebo-Controlled, International Study
Background/Purpose Rheumatoid arthritis (RA) patients develop bone and joint damage due to chronic inflammation mediated by critical cytokines, eg, IL-6. Pre-clinical studies have implicated IL-6…Abstract Number: 1539 • 2014 ACR/ARHP Annual Meeting
Relation Between Number of Previous Anti TNF Agents and Clinical Response in Rheumatoid Arthritis Patients Treated with Rituximab
Background/Purpose Debate is still ongoing regarding rituximab (RTX) as a first or second line biologic therapy. The objective of present study is to assess correlations between…Abstract Number: 2584 • 2014 ACR/ARHP Annual Meeting
Smoking Is Not Associated with Response to TNF Blockers in Patients with Axial Spondyloarthritis
Background/Purpose Smoking has been reported as associated with increase disease activity, more functional impairment, poorer quality of life and more radiographic damages in patients (pts)…Abstract Number: 1522 • 2014 ACR/ARHP Annual Meeting
Impact of Sarilumab on Health Related Quality of Life (HRQoL), Fatigue, and Sleep in Rheumatoid Arthritis Patients at Week 24 – Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study
Background/Purpose: Sarilumab, a fully human monoclonal antibody directed against the IL-6 receptor, demonstrated efficacy in the phase 3 part of the RA-MOBILITY study (NCT01061736) in…Abstract Number: 2559 • 2014 ACR/ARHP Annual Meeting
Vitamin D insufficiency and Deficiency in Two European Cohorts of Patients with Inflammatory Rheumatic Disorders
Background/Purpose Vitamin D plays an important role in the modulation of immune system and epidemiologic data indicate low vitamin D levels in autoimmune diseases such…Abstract Number: 1486 • 2014 ACR/ARHP Annual Meeting
Rapid Onset of Clinical Benefit Is Associated with a Reduction in Validated Biomarkers of Disease in Patients with Rheumatoid Arthritis Treated with Mavrilimumab, a Human Monoclonal Antibody Targeting GM-CSFRá
Background/Purpose Macrophages are pivotal to rheumatoid pathogenesis and their inflammatory products drive many of the signs and symptoms of disease. Mavrilimumab inhibits macrophage activation and…Abstract Number: 2482 • 2014 ACR/ARHP Annual Meeting
Use of Biologic Therapy As Monotherapy in Patients with Rheumatoid Arthritis
Background/Purpose The treatment for Rheumatoid Arthritis (RA) is based on synthetic or biological disease-modifying drugs (DMARDs). Current guidelines recommend biologics in combination with methotrexate as…Abstract Number: 1432 • 2014 ACR/ARHP Annual Meeting
Mortality Ratio of Rheumatoid Arthritis Under Biological Treatment
Mortality Ratio of Rheumatoid Arthritis Under Biological Treatment: HUR-BIO real life results.Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease, which, in many patients, leads…Abstract Number: 2423 • 2014 ACR/ARHP Annual Meeting
Prevalence of Subclinical Synovitis Detected By Ultrasound in Rheumatoid Arthritis and Psoriatic Arthritis Patients Receiving Anti-TNF-α Therapy with Extended Interval of Administration
Background/Purpose To estimate the prevalence of subclinical synovitis detected by ultrasound in rheumatoid arthritis (RA) and psoriatic arthritis (PsA) patients in clinical remission receiving anti-TNFα…
ACR Meeting Abstracts